Boston Scientific (BSX) has invested USD 1.5bln for an approximately 34% equity stake in MiRus
- The agreement includes an exclusive option to acquire MiRus's SIEGEL Balloon Expandable TAVR system through additional aggregate cash payments of USD 3bln, contingent on clinical and regulatory milestones.
- The investment is expected to be immaterial to adj. earnings per share in 2026.
Context
Boston Scientific's $1.5 billion investment for a 34% stake in MiRus highlights their strategic focus on expanding their product offerings, particularly in the cardiovascular space with the TAVR system. While the financial impact on adjusted earnings per share in 2026 is expected to be immaterial, this acquisition could bolster BSX's long-term growth and innovation trajectory, potentially positioning the company favorably within the healthcare equipment sector.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#BOSTON SCIENTIFIC CORP#BSX.US#FOREX#EQUITIES#METALS#EU SESSION#EXCLUSIVE#HEALTH CARE EQUIPMENT#METALS & MINING#HEALTH CARE EQUIPMENT & SUPPLIES#HEALTH CARE EQUIPMENT & SERVICES (GROUP)#S&P 500 INDEX#BSX#DXY#US EQUITIES